ImmunoGen Inc (IMGN)

[skitahoe]

Something appears to be happening, some speculating it could be Oriental partnership. Perhaps news before the Holidays.

Gary

[XenaLives]

Digital footprints?

I got confused for a minute when I saw the same basic picture on both stocks.

[skitahoe]

The Piper Jaffray presentation may have had an influence as well, I'm listening to it as I type, but saw where others were impressed with it.

I believe the bigger news will come out of ASH where hopefully the entire presentation will become available. Among other things I understand that a fast path to approval may be available for IMGN632 in one of the indications being treated. This could have the potential of an approval prior to the conclusion of the Phase 3 for IMGN853, but it's also indicated that a partnership there is certainly in discussion.

Gary

[whytestocks]

News: $IMGN Here's Why ImmunoGen Jumped 12.4% Today

Shares of ImmunoGen (NASDAQ: IMGN) closed Wednesday 12.4% higher as investors piled into the biotech ahead of the American Society of Hematology (ASH) Annual Meeting, which starts Saturday. http://investor.immunogen.com/news-releases/news-release-details/immunogen-present-new-data-imgn632-...

Read the whole news IMGN - Here's Why ImmunoGen Jumped 12.4% Today

[ClayTrader]

* * $IMGN Video Chart 12-04-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $IMGN Video Chart 11-27-2019 * *

Link to Video - click here to watch the technical chart video

[XenaLives]

ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting
November 6, 2019 at 9:01 AM EST

Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN

Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 6, 2019-- ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting the Company’s investigational ADC therapy, IMGN632, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting to be held December 7-10 in Orlando, FL.

IMGN632 is a CD123-targeting ADC in Phase I testing for hematological malignancies, including acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen's novel indolino-benzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against AML blasts, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.

Updated safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients with relapsed/refractory AML and BPDCN will be reported in an oral presentation. Preclinical data related to IMGN632 in combination with Vidaza® (azacitidine) and Venclexta® (venetoclax) and two “trial in progress” posters will also be presented in poster sessions.

“Building on initial data shared at ASH last year, we continue to be encouraged by the anti-leukemia activity and tolerability of IMGN632 in AML and BPCDN,” said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen. “These data support the continued development of IMGN632 as a monotherapy for BPDCN and MRD+ AML, and in combinations for AML. Despite recent advances, including the first drug approved for BPDCN and approvals of targeted therapies for molecularly-defined subsets of AML, the need remains for well-tolerated, effective, and convenient therapies in these diseases.”

http://investor.immunogen.com/node/19011/pdf

[ClayTrader]

* * $IMGN Video Chart 11-05-2019 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $IMGN Why ImmunoGen Stock Is Crushing It Today

Shares of ImmunoGen (NASDAQ: IMGN) were soaring 14.8% higher as of 11:20 a.m. EST on Tuesday. The biotech provided its third-quarter update last Friday. While its financial results were nothing to get excited about, investors cheered its progress with a late-stage clinical study evaluating...

In case you are interested IMGN - Why ImmunoGen Stock Is Crushing It Today

[ClayTrader]

* * $IMGN Video Chart 11-01-2019 * *

Link to Video - click here to watch the technical chart video

[skitahoe]

I believe the 4 presentation they're making at ASH on IMGN632 will spur additional interest in the stock, and hopefully we'll end the year much closer to the high, rather than the lows where we're currently languishing.

As someone in remission after stem cells for ALL I'm happy to hear they're now working with it. I don't believe they're going after the specific form I have, but I know that much off label use is made, so no telling if it could be effective. I'm approaching 5 years post stem cells, but remain on chemo as it greatly diminishes the likelihood of coming out of remission. I hope not to ever need anything more, but it would still nice to know it exists if I do.

Gary

[whytestocks]

News: $IMGN ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results

Full Mirvetuximab Soravtansine Phase 3 FORWARD I and Initial Phase 1b FORWARD II Triplet Data Presented at ESMO Phase 3 MIRASOL Trial for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End Updated IMGN632 AML and BPDCN Monotherapy Data Accepted as Oral Presentation at A...

Read the whole news IMGN - ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results

[ClayTrader]

* * $IMGN Video Chart 10-21-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $IMGN Video Chart 09-30-2019 * *

Link to Video - click here to watch the technical chart video

[skitahoe]

It seems like investors don't like what IMGN said, even though it's essentially what they've been saying all along. A new trial will be started this year that could have IMGN853 approve by about 2022.

I'll admit, their presentation put me to sleep, so I cannot speak to every word, but I believe they've learned much from the failed trial, and the patients in the new trial will be better qualified to receive the maximum benefits. In the failed trial there are certainly a number of patients who're still alive who wouldn't have expected to be with the SOC, but that's not the acceptance criteria. It's sad, investigators can clearly see a certain group that benefits, yet the regulators can't see it being definitive enough to approve the drug with a limited label.

Gary

[skitahoe]

Let's see what's said tomorrow when they're speaking to investors. Hopefully they'll reveal when the new Phase 3 will be initiated, and we'll get further information on their other plans as well.

To all my fellow Jewish investors, L'Shanah Tova.

Gary

[manny371]

https://ih.advfn.com/stock-market/NASDAQ/immunogen-IMGN/stock-news/80820968/immunogen-presents-full-data-from-phase-3-forward

[manny371]

https://ih.advfn.com/stock-market/NASDAQ/immunogen-IMGN/stock-news/80821034/immunogen-presents-initial-data-from-phase-1b-forw

[manny371]

I totally agree

[XenaLives]

Next week is looking good!

 
 09/20/19	16:00:37	3.31	3.27	3.35	200 
 09/20/19	16:00:36	3.31	3.25	3.35	238 
 09/20/19	16:00:35	3.31	3.25	3.35	635 
 09/20/19	16:00:23	3.31	3.25	3.35	739,189 
 09/20/19	16:00:17	3.34	3.25	3.35	5,446 
 09/20/19	16:00:00	3.335	3.30	3.31	4,102,635 
 09/20/19	15:59:58	3.34	3.30	3.31	170 
 09/20/19	15:59:57	3.34	3.30	3.31	200 
 09/20/19	15:59:56	3.34	3.30	3.31	390 
 09/20/19	15:59:55	3.34	3.30	3.31	1,737 
 09/20/19	15:59:54	3.34	3.30	3.31	16,764 
 09/20/19	15:59:52	3.34	3.32	3.33	200 
 09/20/19	15:59:51	3.34	3.32	3.33	452 
 09/20/19	15:59:51	3.34	3.33	3.34	18,197 
 09/20/19	15:59:50	3.34	3.33	3.34	781 
 09/20/19	15:59:49	3.34	3.33	3.34	2,300 
  
  
 

Trades >= 500,000

 
 09/20/19	16:00:23	3.31	3.25	3.35	739,189 
 09/20/19	16:00:00	3.335	3.30	3.31	4,102,635 
 08/28/19	16:00:04	2.59	2.56	2.62	507,800 
 08/28/19	16:00:00	2.59	2.59	2.60	552,263 
 08/19/19	16:17:00	2.85	2.83	2.86	700,000 
 08/12/19	16:00:12	2.83	2.80	2.87	758,200 
 07/22/19	16:00:00	2.29	2.27	2.30	816,900 
 07/22/19	16:00:00	2.29	2.28	2.29	813,299 
 07/18/19	17:36:55	2.31	2.26	2.31	1,169,900 
 07/18/19	16:16:49	2.31	2.26	2.31	1,832,300 
 07/17/19	17:09:42	2.27	2.24	2.32	1,020,100 
 07/12/19	16:00:00	2.43	2.43	2.45	544,862 
 

[skitahoe]

Could be the ESMO presentations, here's a link to a post with the schedule:

https://www.investorvillage.com/smbd.asp?mb=1316&mn=49836&pt=msg&mid=19778711

Gary

[XenaLives]

Nice movement today.. hopefully just the beginning.

[skitahoe]

There should be substantial news between now and the end of the year with presentations expected at ESMO and ASH, but I suspect behind the scenes partnerships may be in discussions, but no telling if or when they'll come to fruition.

Gary

[XenaLives]

Any upcoming news that could close that downward gap?

[52172]

See you guys at 12+

[ClayTrader]

* * $IMGN Video Chart 08-06-2019 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $IMGN Advancements for Global Oncology and Cancer Drugs Market Expected to Show High Growth Potential

August 6, 2019 Palm Beach, FL –August 6, 2019 – According to an industry report , the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from 2018 to 2025....

Read the whole news Advancements for Global Oncology and Cancer Drugs Market Expected to Show High Growth Potential

[ClayTrader]

* * $IMGN Video Chart 08-05-2019 * *

Link to Video - click here to watch the technical chart video

[manny371]

This will do very well

[XenaLives]

Sounds good..

FINANCIAL GUIDANCE

Following the completion of its operational review in June 2019, ImmunoGen has updated its financial guidance for 2019 as follows:

- revenues between $40 million and $45 million;
- operating expenses between $175 million and $180 million; and
- cash and cash equivalents at December 31, 2019, between $165 million and $170 million.

ImmunoGen expects that its current cash, together with expense reductions resulting from the operational changes previously announced and anticipated cash receipts from partners, will fund operations through the release of top-line results from the upcoming mirvetuximab Phase 3 study in platinum-resistant ovarian cancer, which are expected in the first half of 2022.

https://finance.yahoo.com/news/immunogen-reports-recent-progress-second-103000972.html?.tsrc=rss

[skitahoe]

I believe the S-A article on IMGN is presenting what's happening well.

https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?app=1

Gary

[skitahoe]

I believe the S-A article on IMGN is presenting what's happening well.

https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?app=1

Gary

[XenaLives]

Management buying stock - a good sign.

[skitahoe]

I view it as a positive that investors advised against the executive incentives. A few years ago it was tied to share price improvement, and I'm fine with that, but rewards for being at many years lows makes little sense. I don't believe we'll be down here forever, I'm hoping for new highs, at that time, ask us again.

Gary

[ClayTrader]

* * $IMGN Video Chart 06-21-2019 * *

Link to Video - click here to watch the technical chart video

[skitahoe]

Tomorrow is IMGN's Annual Meeting. I don't know if anything major will be announced there, but I certainly hope further guidance will be provided on how they're proceeding with IMGN853, and perhaps if under confidentiality agreements discussions are underway for a ROW partnership for the drug which previously had been discussed by the company. I'm uncertain if IMGN wants all of North America for itself, or just the U.S., but it's been clear that the ROW is open to a partnership.

I believe that IMGN is dramatically undervalued and as more information is released on a few different products that they, and their partners are working on, the price will rise to at least low double digits by the end of the year, or early next year. That said, I found the January $4 calls to attractive to pass up. If I'm right, I'll sell a small fraction of what I've bought to pay for purchasing all the rest as I've promised my wife I wouldn't use more cash to purchase more IMGN.

Gary

[skitahoe]

I agree to a degree, but a ROW partnership for IMGN853 would answer all the questions, and the time is right for it. That partner could potentially gain European approval without further trial. IMGN would easily be in double digits.

On a personal note, I've just had 2 surgeries in under 6 days, so I'm slightly out of it.

Gary

[XenaLives]

A good overview of what is going on with IMGN:

May 20, 2019
A delicate balancing act for Immunogen

Jacob Plieth
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Person balancing on a tightrope
Expect Immunogen to have had a busy weekend: for one, it will likely have been working the phones with its bankers after last week’s wounding setback for its lead asset, mirvetuximab. But discussions should also have turned to how Jazz Pharmaceuticals might be persuaded to opt in to two early assets, IMGN779 and IMGN632.

It is those two projects that some now see as key to Immunogen’s future, but despite promising phase I data in December Jazz, which two years ago bought opt-in rights, has still not bitten the bullet. True, mirvetuximab combo data at Asco could provide a financing window, but in the longer term this asset is a no-hoper.

None of this is to say that Immunogen is desperate; the group ended its first quarter with $270m of cash and virtually no debt. But, as every investor should know, biotechs raise money not when they need it but when they can, and Immunogen has admitted that it is starting an operational review to extend its cash reach.

This was prompted by the US FDA’s refusal to allow a datadredge of the Forward I study to support approval of mirvetuximab monotherapy for platinum-resistant ovarian cancer. Forward I had resoundingly failed to extend progression-free survival in the overall population of folate receptor a (FRa) positive patients.

However, the group had argued that it had seen efficacy in a subgroup of those patients with high levels of FRa, though even here the PFS benefit failed to hit a prespecified level of significance. Still, Immunogen talked up the prospects of the FDA approving mirvetuximab on these data alone, causing its stock to climb nearly 40% at the start of this month.

But last week the shares lost all these gains and more when the FDA refused to entertain such a plan, instead demanding a new prospective pivotal study in FRa-high subjects. The problem was not only the subgroup’s underwhelming PFS data, but the overall remission figures, which were statistically stronger but which the agency said could not be extrapolated to support clinical benefit.

Decision time

Thus Immunogen must now decide whether to devote more attention to the back-up antibody-drug conjugates (ADCs) IMGN779 and IMGN632, whose main attraction is the use of novel class of indolinobenzodiazeprine pseudodimer cytotoxic payloads.

Two years ago Jazz, seeking to boost its oncology presence, paid Immunogen $75m for an option on these and an undisclosed asset. Formally there are two points at which Jazz can opt in to full development: just before pivotal trial start, triggering a “mid double-digit million” milestone, or on regulatory filing, making a “low triple-digit million” fee payable.

Still, licensing deals can be done at any point, and Immunogen would do well to urge Jazz to strike sooner rather than later. An obvious way to do this could be to shop the assets around other companies – the ADC specialist Seattle Genetics springs immediately to mind – and then, assuming that there is interest from these rivals, to impress on Jazz the urgency of the situation.

True, mirvetuximab is far more advanced, and as it is by no means dead it will continue to preoccupy Immunogen and its advisors. A separate study, Forward II, tests the agent alongside other drugs including Keytruda and Avastin – data from the Avastin arm are due to be updated at Asco next month, giving the possibility of a share price uplift.

But the main reason for deep scepticism about mirvetuximab concerns its mechanism of action. The project’s folate receptor target has a proven track record of failure that is due largely to its expression on healthy as well as cancerous cells. Immunogen says 40% of ovarian cancer patients have high levels of FRa, but doubts have been raised about the receptor’s value as a prognostic factor.

A small trial to support accelerated approval might have been affordable, but the worst thing about the Forward I knockback is that the FDA has sent Immunogen a clear message that response rate cannot be used as a surrogate to support mirvetuximab.

The company is thus obliged to run a whole new multicentre study with a survival endpoint. It risks throwing good money after bad.

https://www.evaluate.com/vantage/articles/news/trial-results/delicate-balancing-act-immunogen

[XenaLives]

I believe this is changing:

the FDA remains the gold standard,

[skitahoe]

You may very well be right, but even the Institutions need something positive to build the price when they push to do so. I believe the Phase 3 data clearly indicated that with the proper target the drug will easily be approved. I'm hoping a partnership well before that time will answer all questions about future funding, and drugs beyond IMGN853 will also be nearing approval.

This company still has the potential of exceeding SGEN's market cap, but it needs one or more of it's own drugs to be approved. While European approval is still a possibility, the FDA remains the gold standard, and clearly that will be a few years.

Gary

[XenaLives]

Institutional interest is around 75%. I believe that the biggest reason for this battering is they want retail OUT of IMGN.

[XenaLives]

I believe the EU and the rest of the world are becoming more data driven i their approvals. Also risk/reward is an issue when they believe a drug does not increase risk but can save lives and healthcare system dollars.

Unfortunately saved lives and quality of life are less important in our pay for play system.

[skitahoe]

In the IMGN conference call yesterday they indicated that later this year they'll approach the European authorities to discuss the potential of approval there based on the Phase 3 Trial. In that IMGN has always indicated an intent to do a ROW partnership and not market outside of North America, or possibly just the U.S. themselves, it would make sense for them to make that partnership with BP before approaching the European authorities.

At this point they know what the drug does, they know it can obtain approvals in the right platinum resistant group, and it still may be expanded to other cancers with similar platinum resistance. A potential partner certainly won't pay as much as they would have had the Phase 3 Trial been successful, but they still should be willing to pay substantially for a drug that should be approved in the U.S. and a few years, and could possibly be approved where they'll have the rights much sooner.

I'm not saying this will happen, but it's a strategy that would assure IMGN the funds needed for all the trials it has underway without massive dilution, and it would have the European authorities, and others, working with a BP who already has a presents in their country.

Gary

[XenaLives]

Two reasons, options expiration and they want to shake out the margin call shares.

[north40000]

Why is IMGN trading down today? The morning PR yesterday may be one reason, but the 5:01 PR yesterday should have tempered the morning PR. The evening PR looks encouraging to me;where am I wrong?:

http://ih.advfn.com/stock-market/NASDAQ/immunogen-IMGN/stock-news/79925967/immunogen-announces-mature-data-from-forward-ii-ex

"ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin...



Results to be Presented at 2019 ASCO Annual Meeting

Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease

Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Patients

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with folate receptor alpha (FRa)-positive platinum-resistant ovarian cancer. These findings will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31 – June 4 in Chicago, IL.

“We are pleased that the combination of mirvetuximab plus Avastin has generated significant anti-tumor activity in patients with platinum-resistant disease, with trends toward deeper, more durable responses seen in individuals with higher FRa expression and a favorable tolerability profile. The outcomes observed in patients with medium or high FRa expression are encouraging with respect to those reported in similar patient populations for Avastin plus chemotherapy,” said Anna Berkenblit, M.D., Vice President and Chief Medical Officer of ImmunoGen. “Our goal remains to establish mirvetuximab as the combination agent of choice in ovarian cancer, supporting its use in earlier lines of therapy. These mature data support further exploration of this doublet, as well as the ongoing expansion study evaluating a triplet combination of mirvetuximab with Avastin and carboplatin in patients with platinum-sensitive disease.”

DATA FROM FORWARD II EXPANSION COHORT WITH AVASTIN

Mirvetuximab soravtansine in combination with Avastin in patients with FRa-positive platinum-resistant ovarian cancer continues to demonstrate anti-tumor activity with durable responses and a favorable tolerability profile, particularly among the subset of patients who have received up to two prior lines of therapy and have medium or high levels of FRa expression.

Key findings in 66 patients with platinum-resistant disease include:

In the subset of 16 Avastin-naïve patients with medium or high FRa expression who have received up to two prior lines of therapy, the confirmed overall response rate (ORR) was 56 percent (95% CI 30,80), with a median progression-free survival (PFS) of 9.9 months (95% CI 4.1,15.9) and a median duration of response (DOR) of 12 months (95% CI 6,14.9).
In the overall patient population, the confirmed ORR was 39 percent (95% CI 28,52), with a median PFS of 6.9 months (95% CI 4.9,8.6) and a median DOR of 8.6 months (95% CI 4.9, 14.9).
The combination continues to display a safety profile in-line with the known profiles of each agent, with no new safety signals identified.
“Current treatment options for patients with platinum-resistant ovarian cancer have, unfortunately, exhibited limited efficacy with challenging side effects,” stated David O'Malley, M.D., Professor, Director of Gynecology Clinical Trials and Phase 1 Program, James Cancer Center and The Ohio State University Wexner Medical Center, and FORWARD II Principal Investigator. “Final results from the combination of mirvetuximab soravtansine and Avastin expansion cohort demonstrate very encouraging activity and good tolerability in platinum-resistant ovarian cancer patients, especially those with medium or high FRa expression levels. I look forward to further evaluating mirvetuximab in combination with Avastin as well as in the triplet with carboplatin.”

ASCO PRESENTATION DETAILS

Title: “Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study”
Day/Time: Saturday, June 1, 1:15pm - 4:15pm CDT and discussed at the Poster Discussion Session, 4:30pm-6pm CDT in S406
Lead Author: David M. O’Malley, M.D., The Ohio State University College of Medicine
Location: Hall A
Abstract: 5520
Initial data from an investigator-sponsored trial through the National Comprehensive Cancer Network evaluating mirvetuximab in combination with gemcitabine in patients with FRa-positive recurrent epithelial ovarian, endometrial, or triple negative breast cancer will also be presented. Full dose mirvetuximab appears to combine well with gemcitabine, with a safety profile as expected for these agents and with encouraging anti-tumor activity seen in all three tumor types.

Title: “A phase 1 study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC)”
Day/Time: Saturday, June 1, 8:00am – 11:00am CDT and discussed at the Poster Discussion Session, 3:00pm-4:30pm CDT in E450
Lead Author: Mihaela C. Cristea, MD, City of Hope
Location: Hall A
Abstract: 3009
Additional information can be found at www.asco.org.

ABOUT FORWARD II

FORWARD II is a Phase 1b/2 study of mirvetuximab in combination with Avastin (bevacizumab), carboplatin or Keytruda (pembrolizumab) in patients with FRa-positive platinum-resistant or platinum-agnostic ovarian cancer, primary peritoneal, or fallopian tube tumors, as well as a triplet combination of mirvetuximab plus carboplatin and Avastin in patients with platinum-sensitive ovarian cancer.

ABOUT MIRVETUXIMAB SORAVTANSINE

Mirvetuximab soravtansine (IMGN853) is the first folate receptor alpha (FRa)-targeting ADC. It uses a humanized FRa-binding antibody to target the ADC specifically to FRa-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Avastin® is a registered trademark of Genentech, a member of the Roche Group."

[ClayTrader]

* * $IMGN Video Chart 05-15-2019 * *

Link to Video - click here to watch the technical chart video

[KOmani]

So many shorts here with the midpoint orders going on.

Seems the move is overdone, but the shorts want to get filled low.

Will see if they stuff it low again.

[XenaLives]

Crazy looking tape EOD yesterday..

Paint then Roll call????

 
 05/09/19	17:41:52	3.20	0.00	0.00	1 
 05/09/19	17:41:37	3.20	0.00	0.00	1 
 05/09/19	17:41:22	3.20	0.00	0.00	1 
 05/09/19	17:41:07	3.20	0.00	0.00	1 
 05/09/19	17:23:52	3.05	0.00	0.00	1 
 05/09/19	17:23:37	3.05	0.00	0.00	1 
 05/09/19	17:23:22	3.16	0.00	0.00	1 
 05/09/19	17:23:07	3.16	0.00	0.00	1 
 05/09/19	17:19:52	3.20	0.00	0.00	0 
 05/09/19	17:19:37	3.20	0.00	0.00	0 
 05/09/19	17:19:22	3.20	0.00	0.00	0 
 05/09/19	17:19:07	3.20	0.00	0.00	0 
 05/09/19	16:41:52	3.20	0.00	0.00	8 
 05/09/19	16:41:37	3.20	0.00	0.00	8 
 05/09/19	16:41:22	3.20	0.00	0.00	8 
 05/09/19	16:41:07	3.20	0.00	0.00	8 
 05/09/19	16:37:48	3.20	2.96	3.20	0 
 05/09/19	16:31:23	3.20	3.16	3.22	6,300 
 05/09/19	16:26:43	3.20	3.16	3.22	0 
 05/09/19	16:26:43	3.20	2.96	3.22	1,800 
 05/09/19	16:23:48	3.20	2.96	3.22	0 
 05/09/19	16:18:52	3.20	0.00	0.00	0 
 05/09/19	16:18:37	3.20	0.00	0.00	0 
 05/09/19	16:18:22	3.20	0.00	0.00	0 
 05/09/19	16:18:07	3.20	0.00	0.00	0 
 05/09/19	16:10:26	3.20	2.96	3.20	0 
 05/09/19	16:09:03	3.20	3.15	3.20	0 
 05/09/19	16:07:49	3.20	3.16	3.22	0 
 05/09/19	16:07:13	3.20	3.15	3.22	2,400 
 05/09/19	16:06:29	3.20	3.15	3.22	900 
 05/09/19	16:06:26	3.20	3.15	3.22	1,200 
 05/09/19	16:06:24	3.20	3.15	3.22	1,000 
 05/09/19	16:05:07	3.14	3.15	3.22	0 
 05/09/19	16:03:30	3.14	3.14	3.22	0 
 05/09/19	16:02:49	3.14	3.14	3.21	0 
 05/09/19	16:00:20	3.14	3.13	3.21	100 
 05/09/19	16:00:13	3.20	3.13	3.21	200 
 05/09/19	16:00:11	3.14	3.13	3.21	100 
 05/09/19	16:00:03	3.20	3.13	3.21	600 
 05/09/19	16:00:03	3.20	3.13	3.21	19,400 
 05/09/19	16:00:03	3.20	3.13	3.21	2,300 
 05/09/19	16:00:03	3.20	3.13	3.21	800 
 05/09/19	16:00:03	3.20	3.13	3.21	100 
 05/09/19	16:00:03	3.20	3.13	3.21	6,600 
 05/09/19	16:00:03	3.20	3.13	3.21	0 
  
  
 

[ClayTrader]

* * $IMGN Video Chart 05-06-2019 * *

Link to Video - click here to watch the technical chart video

[skitahoe]

I believe that IMGN's movement since quarterly results were issued is purely based on anticipation that discussions with the FDA on a path to approval for IMGN853 will have a positive conclusion. Clearly the best course would be an agreement to submit a BLA this year based on the Phase 3 for the patient group that received the greatest benefit in the trial. As I see it, the worst case would require an additional trial that added more patients to the group receiving the greatest benefit, which would delay the approval by a couple years. Of course it's also possible that the Phase 2 Trials using drug combinations could result in an approval out of Phase 2.

Some of the combination trial data will be presented at ASCO. The Phase 3 Trial I believe will be discussed a few months later at ESMO. By the time of ESMO I think discussions with the FDA should have concluded, and the company can state what will come next. At the quarterly the company indicated that if discussions with the FDA go well, they'll submit a BLA for IMGN853 approval before the end of this year. If this comes to pass, I believe we'll see a ROW partnership and approval by the end of the first half of next year. I believe that highs not seen in a few years will be reached by the new year if a BLA is being filed, somewhere in the $20's is very possible.

Gary